AMENDMENTS TO THE CLAIMS

1.**(Currently Amended)** A compound of the formula Z:



where;

A is CH or N;

R_1 is a substituent to a carbon atom in the ring containing A selected from

$-S(=O)_pRa$,

where Ra is $-C_1$-C_4 alkyl, -ORx, -NRxRx, -NHNRxRx, -NHNHC(=O)ORx, -NRxOH;

-C(=O)-Rb,

where Rb is $-C_1$-C_4-alkyl, ORx, -NRxRx, -NHNRxRx, $-NHC_1$-C_3-alkyl-C(=O)ORx

-NRxRc,

where Rc is H, C_1-C_4 alkyl, -NRxRx; -C(=O)Rd, -CN, $S(=O)_pRx$

where Rd is Rd is C_1-C_4-alkyl, -ORx, -NRxRx $-C_1$-C_3-alkyl-O-C1-C3alkylC(=O)ORx,

$-C_1$-C_3-alkyl-COORx;

$-C_1$-C_3alkyl-ORx

$-(O-C_1$-C_3alkyl$)_q$-O-Rx

a 5 or 6 membered aromatic ring have 1-3 hetero atoms;

p and q are independently selected from 1 or 2;

Rx is independently selected from H, C_1-C_4 alkyl or acetyl; or a pair of Rx can together with the adjacent N atom form a pyrrolidine, piperidine, piperazine or morpholine ring;

R_2 is a substituent to a carbon atom in the ring containing A and is H, halo, cyano, C_1-C_4-alkyl, haloC_1-C_4-alkyl;
L is –O-, -S(=O)$_r$- or –CH_2-, where r is 0, 1 or 2;
R_3 is H, C_1-C_3 alkyl;
R_4-R_7 are independently selected from H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, haloC_1-C_6 alkyl, C_1-C_6 alkanoyl, haloC_1-C_6 alkanoyl, C_1-C_6 alkoxy, haloC_1-C_6 alkoxy, C_1-C_6 alkyloxyC_1-C_6 alkyl, haloC_1-C_6 alkyloxyC_1-C_6 alkyl, hydroxyC_1-C_6 alkyl, aminoC_1-C_6 alkyl, carboxyC_1-C_6 alkyl, cyanoC_1-C_6 alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto;
X is –(CR_8R_8')$_n$-D-(CR_8R_8')$_m$-;
T is O or S;
D is a bond, –NR_9-, –O-, -S-, -S(=O)- or –S(=O)$_2$-;
n and m are independently 0, 1 or 2, provided that they are not both 0 when D is a bond;
R_8 and R_8' are independently H, C_1-C_3 alkyl, haloC_1-C_3alkyl, hydroxy, or R_8 and R_8' together with their adjacent C atom is –C(=O)-
R_9 is independently H, C_1-C_3 alkyl;
and pharmaceutically acceptable salts and prodrugs thereof;
with the proviso that ~~R~~^{2}-R_1as –C(=O)Rb is not morpholinoketo-.

2. **(Original)** A compound according to claim 1, wherein T is O.

3. **(Original)** A compound according to claim 1, wherein R_3 is H.

4. **(Original)** A compound according to claim 1, wherein the cyclopropyl moiety has an enantiomeric excess of the conformation depicted in the partial



or



formulae:

where X is as defined, Y is the bridge to the (substituted) phenyl ring depicted in formula I and Z is bond to the (thio)urea-pyridyl moiety depicted in formula Z.

5. **(Original)** A compound according to claim 1 wherein the compound of formula Z comprises an enantiomeric excess of the isomer showing negative optical activity.

6. **(Original)** A compound according to claim 1, wherein D is –O-

7. **(Original)** A compound according to claim 6, wherein n is 0 and m is 1.

8. **(Original)** A compound according to claim 1, wherein R_4 is hydrogen, fluoro or hydroxy.

9. **(Original)** A compound according to claim 1, wherein R_5 is hydrogen, fluoro, C_{1-3} alkylcarbonyl or C_1-$_3$alkyloxy.

10. **(Original)** A compound according to claim 1, wherein R_6 is hydrogen, halo, C_1-C_3alkyloxy, C_1-$_3$alkylcarbonyl, cyano or ethynyl.

11. **(Original)** A compound according to claim 10, wherein R_6 is hydrogen, methoxy or fluoro.

12. **(Original)** A compound according to claim 1, wherein R_7 is hydrogen, cyano, halo, C_{1-3}alkyloxy, or C_{1-3}alkylcarbonyl.

13. **(Original)** A compound according to claim 12, wherein R_7 is cyano, fluoro or acetyl.

14. **(Original)** A compound according to claim 1, wherein R_5 and R_6 are H and R_4 and R_7 are fluoro.

15. **(Original)** A compound according to claim 1, wherein R_4 is fluoro, R_5 and R_6 are H, and R_7 is cyano or acetyl.

16. **(Original)** A compound according to claim 1, wherein L is –O-.

17. **(Original)** A compound according to claim 1, wherein R_1 is -$S(=O)_2NRxRx$, $S(=O)_2C_1$-C_4 alkyl, or $S(=O)C_1$-C_4 alkyl.

18. **(Original)** A compound according to claim 17, wherein R_1 is –$S(=O)_2NH_2$, –$S(=O)_2NMe_2$ or –$S(=O)_2$NH-cyclopropyl.

19. **(Original)** A compound according to claim 17, wherein R_1 is -$S(=O)_2$Me or –S(=O)Me.

20. **(Original)** A compound according to claim 1, wherein R_1 is –C(=O)ORx, -C(=O)NRxRx, -C(=O)NHNRxRx or -$C(=O)NHCH_2COORx$.

21. **(Original)** A compound according to claim 20, wherein R_1 is –C(=O)OH, -C(=O)OMe, -$C(=O)NH_2$, -C(=O)NHMe, -$C(=O)NHNH_2$, -$C(=O)NHCH_2COOH$.

22. **(Original)** A compound according to claim 20, wherein R_1 is –C(=O)NRx'-N-morpholine, –C(=O)NRx'-N-piperidine, –C(=O)NRx'-N-pyrrolidine or –C(=O)NRx'-N-piperazine, where Rx is methyl, acetyl or preferably H.

23. **(Original)** A compound according to claim 1, wherein R_1 is –NRxRx, –$N(C=O)C_1$-C_4-alkyl or -$NHC(=O)CH_2OC_1$-C_3-alkyl-COORx.

24. **(Original)** A compound according to claim 23, wherein R_1 is $-NH_2$, -NHC(=O)Me or $NHC(=O)CH_2OCH_2C(=O)OH$.

25. **(Original)** A compound according to claim 1, wherein R_1 is -C_1-C_3-alkyl-COORx;
-C_1-C_3alkyl-ORx, -(O-C_1-C_3alkyl)$_q$-O-Rx or a 5 membered ring having 1-3 hetero atoms.

26. **(Original)** A compound according to claim 25, wherein R_1 is carboxyethyl or a methyl ester thereof, 2-methoxyethoxyethoxy or triazolyl.

27. **(Original)** A compound according to claim 1, wherein R_1 is para to the ether linkage.

28. **(Original)** A compound according to claim 1, wherein the ring containing A is phenyl or pyrid-3-yl.

29. **(Original)** A compound according to claim 1, wherein R_2 is hydrogen or fluoro.

30. **(Original)** A compound according to claim 1 where R_2 is meta to the ether linkage.

31. **(Original)** A compound according to claim 1 denoted N-[(1S,1aR,7bR)-4,7-difluoro-1,1a,2,7b-tetrahydrocyclopropa[c]chromen-1-yl]-N'-[5-(4-(sulfonamido)phenoxy)-2-pyridinyl]urea.

32. **(Original)** A pharmaceutical composition comprising a compound as defined in any preceding claim and a pharmaceutically acceptable vehicle or diluent therefor.

33. **(Original)** A composition according to claim 32, further comprising 1 to 3 additional HIV antivirals.

34. **(Original)** A composition according to claim 32, further comprising a cytochrome P450 modulator, such as ritonavir.

35. **(Currently Amended)** ~~Use of a compound as defined in any of claims 1-31 in the manufacture of a medicament~~A method for the prophylaxis or treatment of HIV-1 infections comprising administering to an individual in need thereof an effective amount of the compound according to claim 1.

36. **(Currently Amended)** ~~Use~~ The method according to claim 35, wherein the HIV-1 infection is a drug escape mutant.

37. **(Currently Amended)** ~~Use~~ The method according to claim 36, wherein the drug escape mutant comprises the L100I and K103N mutations.